Endo Seen Getting Boost From Sale Favored by Fidelity: Real M&A

Endo Health Solutions Inc.’s best hope at regaining investor confidence after losing more than $1 billion in market value is to undo the acquisitions that built the company or find a buyer.

Chief Executive Officer David Holveck is retiring two years after bolting a medical-device business onto his pain-treatment operations. Instead of the “ideal strategic fit” he promised, the stock lost 27 percent since Holveck agreed to pay almost $3 billion for American Medical Systems Holdings Inc., leaving Endo with the lowest valuation in the U.S. specialty pharmaceuticals industry, according to data compiled by Bloomberg.